Evolving developments in the management of COPD
07 Oct 2019
The increasing number of inhaled drugs and devices, as well as contrasting national guidelines and recommendations for pathways of care, appear to increase the complexity of COPD treatment. In particular, the introduction of LABA/LAMA and ICS/LABA/LAMA combination inhalers, and a desire to reduce the use of inhaled corticosteroids has changed the way that patients are treated. This session aims to evaluate the current evidence for optimising and de-escalating therapy in COPD management guidelines.